Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, child: Brain stem glioma
Trial Type:  Treatment
Results 1-22 of 22 for your search:
Start Over
Combination Chemotherapy and Fixed or Flexible Administration of Filgrastim in Treating Younger Patients With Cancer
Phase: Phase III
Type: Treatment
Age: 1 to 25
Trial IDs: 2013-062, NCI-2013-02001, NCT01987596
Crizotinib in Treating Younger Patients with Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL0912, NCI-2011-01937, CDR0000647587, COG-ADVL0912, NCT01182896, P10666, NCT00939770
Selumetinib in Treating Young Patients with Recurrent or Refractory Low Grade Glioma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 21
Trial IDs: PBTC-029B, NCI-2012-03173, CDR667932, PBTC-029, NCT01089101
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: PBTC-033, NCI-2012-00082, 12-C-0213, CDR0000717423, NCT01507324, P12978, NCT01514201
Radiation Therapy in Treating Patients With Recurrent or Progressive Brain Stem Glioma Previously Treated With Radiation Therapy
Phase: Phase II, Phase I
Type: Treatment
Age: 17 and under
Trial IDs: 2011-0804, NCI-2011-03725, NCT01469247
Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 18
Trial IDs: TED12689, NCI-2014-00195, U1111-1128-5704, NCT01751308
Valproic Acid and Radiation Therapy Followed by Maintenance Valproic Acid and Bevacizumab in Treating Young Patients With Newly Diagnosed High-Grade Gliomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 21
Trial IDs: H-24549, NCI-2012-00618, NCT00879437
Everolimus in Treating Younger Patients With Neurofibromatosis Type 1 or Low Grade Gliomas That Did Not Responded to Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: 09452, NCI-2010-01929, DOD W81XWH-05-1-0615, NCT01158651
Radiation Therapy, Bevacizumab, Erlotinib Hydrochloride, or Temozolomide in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 18
Trial IDs: 10-321, NCI-2011-03059, DFCI 10-321, NCT01182350
Poly ICLC in Treating Younger Patients With Recurrent or Progressive Low Grade Gliomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 21
Trial IDs: Poly-ICLC, NCI-2013-02084, NCT01188096
Proton Beam Radiation Therapy in Treating Younger Patients with Brain Tumors
Phase: Phase II
Type: Natural history/Epidemiology, Treatment
Age: 1 to 25
Trial IDs: 10-206, NCI-2011-00201, NCT01288235
Bevacizumab and Everolimus in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Phase: Phase I
Type: Treatment
Age: 21 and under
Trial IDs: RADBEV, NCI-2011-01149, NCT00756340
Crizotinib and Dasatinib in Treating Younger Patients with Recurrent or Progressive Diffuse Intrinsic Pontine Glioma or High-Grade Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 21
Trial IDs: SJHG12, NCI-2012-01240, NCT01644773
Melphalan in Treating Patients With Progressive Diffuse Intrinsic Pontine Gliomas
Phase: Phase I
Type: Treatment
Age: 1 month to 17 years
Trial IDs: J11164, NCI-2013-00515, NA_00069122, NCT01688401
Activated Natural Killer Cells with or without Recombinant Interleukin-15 in Treating Younger Patients with Refractory Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 25
Trial IDs: 13-C-0152, NCI-2013-01215, 09-25-0099, 130152, P9493_A06PAMDREVW01, 9493, NCT01875601
WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 37 months to 21 years
Trial IDs: ADVL1217, NCI-2013-01602, COG-ADVL1217, NCT01922076
Palbociclib Isethionate in Treating Younger Patients with Recurrent, Progressive, or Refractory Central Nervous System Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: PBTC-042, NCI-2014-00640, NCT02255461
Lenalidomide and Radiation Therapy in Treating Younger Patients with Pontine Glioma or High-Grade Glioma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: 10-C-0219, NCI-2011-02539, 100219, CDR0000687467, NCI-10-C-0219, NCT01226940, 8449, NCT01222754
Informed Consent to Enroll Younger Patients with Newly Diagnosed Cancer in the Childhood Cancer Research Network
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and under
Trial IDs: ACCRN07, NCI-2009-00331, 10-C-0111, CDR0000069496, NCT01117168
Imiquimod and Vaccine Therapy in Treating Younger Patients with Recurrent or Progressive Glioblastoma Multiforme or Diffuse Intrinsic Pontine Glioma
Phase: No phase specified
Type: Treatment
Age: 3 and over
Trial IDs: 2009LS136, NCI-2012-00322, NCT01400672
Start Over